Matthew L. Ulrickson

1.6k citations
35 papers · 401 indexed · 1 hit paper · h-index 8
Topics
CAR-T cell therapy research (21 papers)Lymphoma Diagnosis and Treatment (12 papers)Chronic Lymphocytic Leukemia Research (5 papers)

In The Last Decade

Matthew L. Ulrickson

27 papers receiving 396 citations

Hit Papers

Axicabtagene ciloleucel as first-line therapy in high-ris...2022202620232024202250100150

Peers

Matthew L. Ulrickson
Comparison fields: 5 of 41
  • Oncology 313
  • Pathology and Forensic Medicine 156
  • Molecular Biology 77
  • Genetics 70
  • Genetics 66
Replace Alessandro Crotta with:
Alessandro Crotta United States
Marie-Elisabeth Goebeler Germany
Alessandro Previtali United States
Christine Dehner United States
Houston Holmes United States
Barbara S. Pender United States
Robin Sanderson United Kingdom
Dena DeMarco United States
Bryan Do United States
Paul Maciocia United Kingdom
Matthew L. Ulrickson relative to Alessandro Crotta United States Alessandro Crotta's profile →
Citations per field
00.5×
Alessandro Crotta · 1×
Citations per year

Countries citing papers authored by Matthew L. Ulrickson

Since Specialization
Citations

This map shows the geographic impact of Matthew L. Ulrickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew L. Ulrickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew L. Ulrickson more than expected).

Fields of papers citing papers by Matthew L. Ulrickson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew L. Ulrickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew L. Ulrickson. The network helps show where Matthew L. Ulrickson may publish in the future.

Co-authorship network of co-authors of Matthew L. Ulrickson

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew L. Ulrickson. A scholar is included among the top collaborators of Matthew L. Ulrickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew L. Ulrickson. Matthew L. Ulrickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 0
3 1
4 0
5 0
6 0
7 0
8
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialbreakdown →
186
9 4
10 3
11 3
12 3
13 3
14 15
15 12
16 34
17 4
18 12
19 29
20 41

About Matthew L. Ulrickson

Matthew L. Ulrickson is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics, having authored 35 papers that have together received 401 indexed citations. Recurring topics across this work include CAR-T cell therapy research (21 papers), Lymphoma Diagnosis and Treatment (12 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Oncology (313 citations), Pathology and Forensic Medicine (156 citations) and Genetics (70 citations). Matthew L. Ulrickson has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Olalekan O. Oluwole, Natasha Kekre, Sattva S. Neelapu, Yi Lin, Chaitra S. Ujjani, Julio C. Chávez, Alex F. Herrera, Peter A. Riedell, Michael Dickinson and Sven de Vos. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026